About: SR9009

An Entity of Type: chemical substance, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

SR9009, also known as Stenabolic, is a research drug that was developed by professor Thomas Burris of the Scripps Research Institute as an agonist of Rev-ErbA (i.e., increases the constitutive repression of genes regulated by Rev-ErbA) with a half-maximum inhibitory concentration (IC50) = 670 nM for Rev-ErbAα and IC50 = 800 nM for Rev-ErbAβ. Activation of Rev-ErbA-α by SR9009 in mice increases exercise capacity by increasing mitochondria counts in skeletal muscle.

Property Value
dbo:abstract
  • SR9009, also known as Stenabolic, is a research drug that was developed by professor Thomas Burris of the Scripps Research Institute as an agonist of Rev-ErbA (i.e., increases the constitutive repression of genes regulated by Rev-ErbA) with a half-maximum inhibitory concentration (IC50) = 670 nM for Rev-ErbAα and IC50 = 800 nM for Rev-ErbAβ. Activation of Rev-ErbA-α by SR9009 in mice increases exercise capacity by increasing mitochondria counts in skeletal muscle. Abuse of SR9009 has been reported within the bodybuilding community, resulting in SR9009 being placed on the World Anti-Doping Agency list of prohibited drugs. SR9009 and the related SR9011 drug are described as "Hormone and Metabolic Modulators". (en)
dbo:casNumber
  • 1379686-30-2
dbo:chEMBL
  • 1961796
dbo:fdaUniiCode
  • X5DCA09N30
dbo:pubchem
  • 57394020
dbo:thumbnail
dbo:wikiPageID
  • 40319032 (xsd:integer)
dbo:wikiPageLength
  • 4308 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID
  • 1081146196 (xsd:integer)
dbo:wikiPageWikiLink
dbp:c
  • 20 (xsd:integer)
dbp:casNumber
  • 1379686 (xsd:integer)
dbp:chembl
  • 1961796 (xsd:integer)
dbp:chemspiderid
  • 28487410 (xsd:integer)
dbp:cl
  • 1 (xsd:integer)
dbp:h
  • 24 (xsd:integer)
dbp:iupacName
  • ethyl-3-pyrrolidine-1-carboxylate (en)
dbp:molecularWeight
  • 437.940260 (xsd:double)
dbp:n
  • 3 (xsd:integer)
dbp:o
  • 4 (xsd:integer)
dbp:pubchem
  • 57394020 (xsd:integer)
dbp:s
  • 1 (xsd:integer)
dbp:smiles
  • CCOCN1CCCCNCC3=CC=C[N+][O-] (en)
dbp:stdinchi
  • 1 (xsd:integer)
dbp:stdinchikey
  • MMJJNHOIVCGAAP-UHFFFAOYSA-N (en)
dbp:unii
  • X5DCA09N30 (en)
dbp:width
  • 240 (xsd:integer)
dbp:wikiPageUsesTemplate
dct:subject
gold:hypernym
rdf:type
rdfs:comment
  • SR9009, also known as Stenabolic, is a research drug that was developed by professor Thomas Burris of the Scripps Research Institute as an agonist of Rev-ErbA (i.e., increases the constitutive repression of genes regulated by Rev-ErbA) with a half-maximum inhibitory concentration (IC50) = 670 nM for Rev-ErbAα and IC50 = 800 nM for Rev-ErbAβ. Activation of Rev-ErbA-α by SR9009 in mice increases exercise capacity by increasing mitochondria counts in skeletal muscle. (en)
rdfs:label
  • SR9009 (en)
owl:sameAs
prov:wasDerivedFrom
foaf:depiction
foaf:isPrimaryTopicOf
is dbo:wikiPageWikiLink of
is foaf:primaryTopic of
Powered by OpenLink Virtuoso    This material is Open Knowledge     W3C Semantic Web Technology     This material is Open Knowledge    Valid XHTML + RDFa
This content was extracted from Wikipedia and is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License